Doubts have been raised as to the administration of O3 to oncological patients since the role of Nrf2 in cancer initiation, progression, and treatment is controversial (reviewed in [211]), and interference between O3 and doxorubicin was observed in a human breast cancer cell line [212]. This evidence concerns the gene NFE2L2 and breast carcinoma.